YEAR-END AND Q4 REPORT 2007

Report this content

2007 in brief (Group)

• Revenues for the period amounted to MSEK 16.2 (2.6)

• EBIT amounted to MSEK -61.3 (-21.2)

• Profit for the period amounted to MSEK -62.9 (-21.2)

• Earnings per share, basic and diluted, amounted to -6.05 SEK
(-4.06)

• Listing on NGM Equity (SE) and Oslo Axess (NO)

• Strategic acquisition of the Danish biotech company Nordic
Phytopharma A/S (now SCN Denmark A/S)

• 16 new contracts signed for Coldizin and Immulina world-wide

• Has entered US market with first of many products

• Goal: to launch two more products in USA in 2008 and add
more markets for existing products


CONTACT INFORMATION
Ulf Söderberg, CEO
Mobile: +46 708 13 22 81
E-mail: us@scnutrition.com

Thomas Christensen, CFO
Mobile: +47 922 55 444
E-mail: tc@scnutrition.com

Documents & Links